CAPRICOR THERAPEUTICS, INC.
CAPR · XNASCIK 1133869fmd_0F05QJQAFVXANY2CMHZ14CDZZPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2005 to Sep 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4 | 3 | 2 | 1 | 0 | 0 | 3 | 25 | 22 | 0 |
| Research and development | 16 | 11 | 12 | 5 | 8 | 14 | 22 | 36 | 50 | 84 |
| Total operating expenses | 21 | 16 | 17 | 9 | 14 | 21 | 32 | 49 | 65 | 108 |
| Operating income | (17) | (13) | (15) | (8) | (14) | (21) | (30) | (24) | (43) | (108) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – | 0 | 3 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 6 |
| Other non-operating income (expense) | (2) | 15 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 |
| Income before taxes | – | – | – | – | – | – | – | – | (40) | (105) |
| Income tax expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (40) | (105) |
| Net income | (19) | 2 | (15) | (8) | (14) | (20) | (29) | (22) | (40) | (105) |